- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02447796
Dexmedetomidine and Propofol As Sole Sedative Agent for Patients Undergoing Arteriovenous Fistula Surgery
May 18, 2015 updated by: Ozlem Ozmete, Baskent University
A Comparative Study of Dexmedetomidine and Propofol As Sole Sedative Agent for Patients With End-Stage Renal Disease Undergoing Arteriovenous Fistula Surgery
The investigators designed a prospective randomized study to compare the conventionally used sedative drug propofol with a latest alternative dexmedetomidine (DEX), in patients with end-stage renal disease undergoing arteriovenous fistula (AVF) surgery.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
48
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ozlem Ozmete, MD
- Phone Number: 2461 +903223272727
- Email: ozlemyilma@yahoo.com
Study Contact Backup
- Name: Cagla Bali, MD
- Phone Number: +905320613026
- Email: caglaetike@hotmail.com
Study Locations
-
-
-
Adana, Turkey, 01250
- Recruiting
- Baskent University School of Medicine Adana Research and Teaching Center
-
Contact:
- Ozlem Ozmete, MD
- Phone Number: +903223272727
- Email: ozlemyilma@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Inclusion criteria were patients undergoing arteriovenous fistula (AVF) surgery aged between 20-70 with end stage renal failure on dialysis treatment.
Exclusion Criteria:
- Exclusion criteria were decompensated respiratory or heart failure, liver failure, obesity (body mass index>30), severe obstructive sleep apnea, need for additional different drugs for sedation, chronic use of alcohol, opioids or other sedative drugs,mental disorders, cognitive disorders, language problems and history of allergy to any medications used in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Propofol
Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24)
|
Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).
Other Names:
|
Active Comparator: Dexmedetomidine (DEX)
DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24)
|
DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of adverse effects such as respiratory and hemodynamic events
Time Frame: up to 24 hours postoperative
|
up to 24 hours postoperative
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The sedation onset time with using BIS and recovery times during the procedure.
Time Frame: up to 24 hours postoperative
|
up to 24 hours postoperative
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anis Aribogan, Prof md, Başkent University School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2015
Primary Completion (Actual)
May 1, 2015
Study Completion (Anticipated)
July 1, 2015
Study Registration Dates
First Submitted
May 11, 2015
First Submitted That Met QC Criteria
May 18, 2015
First Posted (Estimate)
May 19, 2015
Study Record Updates
Last Update Posted (Estimate)
May 19, 2015
Last Update Submitted That Met QC Criteria
May 18, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Congenital Abnormalities
- Pathological Conditions, Anatomical
- Cardiovascular Abnormalities
- Vascular Malformations
- Arteriovenous Malformations
- Vascular Fistula
- Fistula
- Arteriovenous Fistula
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Propofol
- Dexmedetomidine
Other Study ID Numbers
- KA 15/60
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arteriovenous Fistula
-
Medtronic EndovascularCompletedFistula | Arteriovenous Fistula | Arteriovenous Fistula Stenosis | Arteriovenous Fistula OcclusionNew Zealand, United States, Japan
-
MedtronicRecruitingFistula | Arteriovenous Fistula | Arteriovenous Fistula Stenosis | Arteriovenous Fistula OcclusionUnited States
-
Hospital General Universitario Gregorio MarañonSpanish Society of NephrologyCompletedArteriovenous Fistula Stenosis | Arteriovenous Fistula ThrombosisSpain
-
Ai PengRecruitingArteriovenous Fistula Flow Monitoring | Early Detection of Complications of Arteriovenous Fistula | VoiceprintChina
-
Rennes University HospitalTerminatedStenosis of Arteriovenous Dialysis FistulaFrance
-
Fundación Pública Andaluza Progreso y SaludCompletedArteriovenous Fistula Renal Dialysis Devices ObstructionSpain
-
Centre hospitalier de l'Université de Montréal...Biotronik Canada IncCompletedArteriovenous Graft | Arteriovenous FistulaeCanada
-
Henry Ford Health SystemAnalogic CorporationCompletedArteriovenous Fistula, CannulationUnited States
-
National Taiwan University HospitalCompletedArteriovenous Fistula OcclusionTaiwan
-
Acotec Scientific Co., LtdCompleted
Clinical Trials on Propofol
-
Hopital FochCompleted
-
Konkuk University Medical CenterCompletedCoronary Artery Disease | Valvular Heart DiseaseKorea, Republic of
-
University Medical Center GroningenCompletedAnesthesia | Hemodynamic Instability | Interaction | Disorder of Oxygen TransportNetherlands
-
Asan Medical CenterCompletedPopulation Pharmacokinetics/Pharmacodynamics (PK/PD) of Microemulsion Propofol in Healthy VolunteersHealthyKorea, Republic of
-
Tiva GroupMedtronic - MITGCompleted
-
Pontificia Universidad Catolica de ChileCompletedSurgery | Anesthesia | Depth of Anesthesia | NeonateChile
-
Mansoura UniversityCompleted
-
KVG Medical College and HospitalUnknown
-
Acibadem UniversityCompleted